Iranian Journal of Radiology

Published by: Kowsar

Impact of FDG-PET and Dynamic Contrast-Enhanced MRI in Comparison with DWI for N-Staging in Lung Cancer Patients

Paul Flechsig 1 , 2 , * , Heike Zabeck 3 , Sebastian Reubold 1 , Christos Sachpekidis 1 , 4 , Hendrik Rathke 1 , Manuel Röhrich 1 , Tim Holland-Letz 5 , Claus-Peter Heussel 6 , Alexander Harms 7 , Hans-Ulrich Kauczor 2 , 8 , Uwe Haberkorn 1 , 2 , 4 and Frederik L. Giesel 1 , 4 , 9
Authors Information
1 Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
2 Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
3 Thorax Clinic at Heidelberg University, Division of Thoracic Surgery, Heidelberg, Germany
4 Clinical Cooperation Unit, Department of Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
5 Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany
6 Thorax Clinic at Heidelberg University, Division of Diagnostic and Interventional Radiology with Nuclear Medicine, Heidelberg, Germany
7 Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
8 Diagnostic and Interventional Radiology Clinic, University Hospital Heidelberg, Heidelberg, Germany
9 Department of Radiology, Columbia University Medical Center, New York, United States
Article information
  • Iranian Journal of Radiology: January 31, 2019, 16 (1); e68638
  • Published Online: December 1, 2018
  • Article Type: Research Article
  • Received: March 13, 2018
  • Revised: August 27, 2018
  • Accepted: September 3, 2018
  • DOI: 10.5812/iranjradiol.68638

To Cite: Flechsig P, Zabeck H, Reubold S, Sachpekidis C, Rathke H, et al. Impact of FDG-PET and Dynamic Contrast-Enhanced MRI in Comparison with DWI for N-Staging in Lung Cancer Patients, Iran J Radiol. 2019 ; 16(1):e68638. doi: 10.5812/iranjradiol.68638.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Kratochwil C, Haberkorn U, Giesel FL. [PET/CT for diagnostics and therapy stratification of lung cancer]. Radiologe. 2010;50(8):684-91. German. doi: 10.1007/s00117-009-1960-6. [PubMed: 20652216].
  • 2. Abramyuk A, Appold S, Zophel K, Hietschold V, Baumann M, Abolmaali N. Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy--a retrospective study. Lung Cancer. 2012;78(2):148-52. doi: 10.1016/j.lungcan.2012.08.001. [PubMed: 22922126].
  • 3. Koenigkam-Santos M, Optazaite E, Sommer G, Safi S, Heussel CP, Kauczor HU, et al. Contrast-enhanced magnetic resonance imaging of pulmonary lesions: Description of a technique aiming clinical practice. Eur J Radiol. 2015;84(1):185-92. doi: 10.1016/j.ejrad.2014.10.007. [PubMed: 25455411].
  • 4. Tournoy KG, Keller SM, Annema JT. Mediastinal staging of lung cancer: novel concepts. Lancet Oncol. 2012;13(5):e221-9. doi: 10.1016/S1470-2045(11)70407-7. [PubMed: 22554550].
  • 5. Rami-Porta R, Call S. Invasive staging of mediastinal lymph nodes: Mediastinoscopy and remediastinoscopy. Thorac Surg Clin. 2012;22(2):177-89. doi: 10.1016/j.thorsurg.2011.12.003. [PubMed: 22520285].
  • 6. Flechsig P, Kratochwil C, Schwartz LH, Rath D, Moltz J, Antoch G, et al. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer. J Nucl Med. 2014;55(4):559-64. doi: 10.2967/jnumed.113.128504. [PubMed: 24525209].
  • 7. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]. Pneumologie. 2011;65(8):e51-75. German. doi: 10.1055/s-0030-1256562. [PubMed: 21830177].
  • 8. Schaarschmidt BM, Grueneisen J, Metzenmacher M, Gomez B, Gauler T, Roesel C, et al. Thoracic staging with (18)F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to (18)F-FDG PET/CT? Eur Radiol. 2017;27(2):681-8. doi: 10.1007/s00330-016-4397-0. [PubMed: 27180186].
  • 9. Lee SM, Goo JM, Park CM, Yoon SH, Paeng JC, Cheon GJ, et al. Preoperative staging of non-small cell lung cancer: Prospective comparison of PET/MR and PET/CT. Eur Radiol. 2016;26(11):3850-7. doi: 10.1007/s00330-016-4255-0. [PubMed: 26883332].
  • 10. Heusch P, Buchbender C, Kohler J, Nensa F, Gauler T, Gomez B, et al. Thoracic staging in lung cancer: Prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT. J Nucl Med. 2014;55(3):373-8. doi: 10.2967/jnumed.113.129825. [PubMed: 24504054].
  • 11. Huellner MW, de Galiza Barbosa F, Husmann L, Pietsch CM, Mader CE, Burger IA, et al. TNM staging of non-small cell lung cancer: Comparison of PET/MR and PET/CT. J Nucl Med. 2016;57(1):21-6. doi: 10.2967/jnumed.115.162040. [PubMed: 26471696].
  • 12. Giesel FL, Schneider F, Kratochwil C, Rath D, Moltz J, Holland-Letz T, et al. Correlation between SUVmax and CT radiomic analysis using lymph node density in PET/CT-based lymph node staging. J Nucl Med. 2017;58(2):282-7. doi: 10.2967/jnumed.116.179648. [PubMed: 27660141].
  • 13. Flechsig P, Frank P, Kratochwil C, Antoch G, Rath D, Moltz J, et al. Radiomic analysis using density threshold for FDG-PET/CT-based n-staging in lung cancer patients. Mol Imaging Biol. 2017;19(2):315-22. doi: 10.1007/s11307-016-0996-z. [PubMed: 27539308].
  • 14. Schaefer JF, Vollmar J, Schick F, Vonthein R, Seemann MD, Aebert H, et al. Solitary pulmonary nodules: Dynamic contrast-enhanced MR imaging--perfusion differences in malignant and benign lesions. Radiology. 2004;232(2):544-53. doi: 10.1148/radiol.2322030515. [PubMed: 15215548].
  • 15. Sauter AW, Spira D, Schulze M, Pfannenberg C, Hetzel J, Reimold M, et al. Correlation between [(1)(8)F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2013;40(5):677-84. doi: 10.1007/s00259-012-2318-2. [PubMed: 23306806].
  • 16. Ohno Y, Hatabu H, Takenaka D, Adachi S, Kono M, Sugimura K. Solitary pulmonary nodules: Potential role of dynamic MR imaging in management initial experience. Radiology. 2002;224(2):503-11. doi: 10.1148/radiol.2242010992. [PubMed: 12147849].
  • 17. Pauls S, Mottaghy FM, Schmidt SA, Kruger S, Moller P, Brambs HJ, et al. Evaluation of lung tumor perfusion by dynamic contrast-enhanced MRI. Magn Reson Imaging. 2008;26(10):1334-41. doi: 10.1016/j.mri.2008.04.005. [PubMed: 18538522].
  • 18. Zou Y, Zhang M, Wang Q, Shang D, Wang L, Yu G. Quantitative investigation of solitary pulmonary nodules: Dynamic contrast-enhanced MRI and histopathologic analysis. AJR Am J Roentgenol. 2008;191(1):252-9. doi: 10.2214/AJR.07.2284. [PubMed: 18562755].
  • 19. Chang YC, Yu CJ, Chen CM, Hu FC, Hsu HH, Tseng WY, et al. Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging. 2012;36(2):387-96. doi: 10.1002/jmri.23660. [PubMed: 22517425].
  • 20. Kono R, Fujimoto K, Terasaki H, Muller NL, Kato S, Sadohara J, et al. Dynamic MRI of solitary pulmonary nodules: Comparison of enhancement patterns of malignant and benign small peripheral lung lesions. AJR Am J Roentgenol. 2007;188(1):26-36. doi: 10.2214/AJR.05.1446. [PubMed: 17179342].
  • 21. Mamata H, Tokuda J, Gill RR, Padera RF, Lenkinski RE, Sugarbaker DJ, et al. Clinical application of pharmacokinetic analysis as a biomarker of solitary pulmonary nodules: Dynamic contrast-enhanced MR imaging. Magn Reson Med. 2012;68(5):1614-22. doi: 10.1002/mrm.24150. [PubMed: 22231729]. [PubMed Central: PMC3335927].
  • 22. Schaefer WM, Kaiser HJ, Kuehl H, Koch KC, Nowak B, Buell U. Quantification of left ventricular volumes and ejection fraction from 16- and rebinned 8-frame gated 99mTc-tetrofosmin SPECT. Comparison of 4D-MSPECT and QGS. Nuklearmedizin. 2007;46(1):22-8. doi: 10.1055/s-0037-1616622. [PubMed: 17299651].
  • 23. Spira D, Wecker M, Spira SM, Hetzel J, Spengler W, Sauter A, et al. Does volume perfusion computed tomography enable differentiation of metastatic and non-metastatic mediastinal lymph nodes in lung cancer patients? A feasibility study. Cancer Imaging. 2013;13(3):323-31. doi: 10.1102/1470-7330.2013.0033. [PubMed: 23876521]. [PubMed Central: PMC3719054].
  • 24. Ye X, Chen S, Tian Y, You B, Zhang W, Zhao Y, et al. A preliminary exploration of the intravoxel incoherent motion applied in the preoperative evaluation of mediastinal lymph node metastasis of lung cancer. J Thorac Dis. 2017;9(4):1073-80. doi: 10.21037/jtd.2017.03.110. [PubMed: 28523162]. [PubMed Central: PMC5418274].
  • 25. Schaarschmidt BM, Buchbender C, Nensa F, Grueneisen J, Gomez B, Kohler J, et al. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI. PLoS One. 2015;10(1). e0116277. doi: 10.1371/journal.pone.0116277. [PubMed: 25574968]. [PubMed Central: PMC4289066].
  • 26. Liang L, Luo X, Lian Z, Chen W, Zhang B, Dong Y, et al. Lymph node metastasis in head and neck squamous carcinoma: Efficacy of intravoxel incoherent motion magnetic resonance imaging for the differential diagnosis. Eur J Radiol. 2017;90:159-65. doi: 10.1016/j.ejrad.2017.02.039. [PubMed: 28583628].
  • 27. Fraioli F, Screaton NJ, Janes SM, Win T, Menezes L, Kayani I, et al. Non-small-cell lung cancer resectability: Diagnostic value of PET/MR. Eur J Nucl Med Mol Imaging. 2015;42(1):49-55. doi: 10.1007/s00259-014-2873-9. [PubMed: 25120040]. [PubMed Central: PMC4244545].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments